Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 2/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | TYK2 | P29597 | 1/20 | 0.32 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.31 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.31 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.31 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6810852 | 0.92 | HTR2C (0.32) | HTR2CHTR2AHTR2B | |
| SCHEMBL6810658 | 0.91 | TYK2 (0.35) | HTR2CHTR2AHTR2BTYK2 | |
| SCHEMBL6502965 | 0.89 | HTR2A (0.36) | HTR2CHTR2AHTR2B | |
| SCHEMBL6490790 | 0.88 | HTR2C (0.36) | HTR2CHTR2AHTR2B | |
| SCHEMBL6490191 | 0.87 | HTR2C (0.36) | HTR2CHTR2AHTR2B | |
| SCHEMBL6493587 | 0.86 | CHEK1 (0.31) | HTR2CHTR2AHTR2B | |
| SCHEMBL6502241 | 0.85 | HTR2C (0.38) | HTR2CHTR2AHTR2B | |
| SCHEMBL6810041 | 0.83 | TYK2 (0.35) | TYK2PIK3CDPIK3R1PIK3CAPIK3CB | |
| SCHEMBL6789302 | 0.83 | HTR2C (0.35) | HTR2CHTR2AHTR2B | |
| SCHEMBL6501489 | 0.82 | PARP14 (0.35) | HTR2CHTR2AHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6849619-B2 | Substituted pyridoindoles as serotonin agonists and antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-02-01 | — | — | US | disclosed |
| US-20040186094-A1 | Substituted pyridoindoles as serotonin agonists and antagonists | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186094-A1 | Substituted pyridoindoles as serotonin agonists and antagonists | HTR1A, HTR1B, HTR7 | HTR2C 11/4885HTR2A 21/4885HTR2B 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.